English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Blood transfusion is a necessary treatment for cancer patients . Among multiple malignant cancers, the pathological characteristics of hepatocellular carcinoma (HCC), such as suppressed hematopoietic function, chronic blood loss, and intraoperative bleeding, blood transfusion is a vital treatment for HCC patients. However, several clinical and laboratory studies have confirmed the relationship between transfusion and the increased risk of recurrence and mortality in HCC (1-3). Storage time has been confirmed to influence the quality of red blood cells (RBCs), and the aging of RBCs in the storage bag (storage lesion) results in detrimental clinical outcomes, such as acute kidney/lung injury, pneumonia, infection, and cancer recurrence (4,5). Various biological molecules in stored RBCs are involved in transfusion-related immunomodulation (6) and may affect the recurrence and prognosis of HCC patients after the transfusion of aged RBCs. Ubiquitin (Ub) is a highly conserved heat-stable 8.5 kDa Original Article

Extracellular ubiquitin inhibits the apoptosis of hepatoma cells via the involvement of macrophages